Trial Profile
A retrospective study of ibrutinib in patients with relapsed chronic-lymphocytic-leukaemia after allogeneic stem cell transplantation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Feb 2016
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 06 Feb 2016 New trial record
- 11 Jan 2016 Results (n=5, cutoff date 12 November 2015) published in the Bone Marrow Transplantation.